Bloomberg Intelligence’s Sam Fazeli discusses AbbVie’s $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie’s presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on “Bloomberg Open Interest.” (Source: Bloomberg)
Trending
- British national tests positive for Ebola in DRC
- U of A study abroad participation reaches record high as students seek experiences beyond classroom
- Reps propose fines, licence withdrawal for hospitals that delay emergency treatment
- Nigerian lawmakers propose six-month jail term for doctors, nurses who delay emergency treatment
- Six climate measures could save 1.6 million lives yearly – WHO
- Nigeria to Expand Eye Care to 25m People, Accelerate Universal Health Coverage – THISDAYLIVE
- School Assembly News Headlines (November 5, 2026): Top National, World, Education, Business News | Education News
- El Niño, Nigeria’s next climate test
